Alnylam Pharms Inc Drug Patent Portfolio

Alnylam Pharms Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Alnylam Pharms Inc News

BridgeBio receives FDA approval, introducing new competition for Pfizer's popular cardiovascular medication.

25 Nov, 2024

Detailed data reveals significant benefit of Alnylam's heart medication vutrisiran, as reported by STAT News

30 Aug, 2024

Alnylam Stock Shows High Potential in the Biopharmaceutical Industry according to TradingView

18 Jul, 2024

Alnylam Pharma's Buy Rating Reconfirmed as Zilebesiran demonstrates significant growth potential

06 Mar, 2024

See More